# Cost-effectiveness of TPMT Pharmacogenetics

> **NCT00521950** · NA · COMPLETED · sponsor: **ZonMw: The Netherlands Organisation for Health Research and Development** · enrollment: 853 (actual)

## Conditions studied

- Inflammatory Bowel Diseases
- Crohn Disease
- Ulcerative Colitis

## Interventions

- **GENETIC:** TPMT genotyping; Drug: azathioprine or 6-mercaptopurine
- **DRUG:** azathioprine (AZA) or 6-mercaptopurine (6-MP)

## Key facts

- **NCT ID:** NCT00521950
- **Lead sponsor:** ZonMw: The Netherlands Organisation for Health Research and Development
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 853 (ACTUAL)
- **Last updated:** 2014-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00521950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00521950, "Cost-effectiveness of TPMT Pharmacogenetics". Retrieved via AI Analytics 2026-06-17 from https://api.ai-analytics.org/clinical/NCT00521950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*